Loading...
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...
Na minha lista:
| Udgivet i: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6747861/ https://ncbi.nlm.nih.gov/pubmed/31555463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217319875471 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|